The efficacy and tolerability of omalizumab in patients with moderate to severe persistent allergic asthma in Malta : A real life experience
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2017 Results (n=34) assessing sex differences in the efficacy, safety, and tolerability of omalizumab published in the Annals of Allergy, Asthma and Immunology.
- 22 Nov 2013 New trial record
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.